On November 20, 2019 Suzhou’s BrightGene Bio-Medical reported that completed a $74 million IPO on the Shanghai Star Exchange and climbed 141% higher in its first trading session, giving the company a market capitalization of $1.8 billion (Press release, ChinaBio, NOV 20, 2019, View Source [SID1234551555]). Founded in 2001, BrightGene develops novel drugs as well as hard-to-make generics, APIs and finished drugs. The company is developing immunoncology treatments, oral GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumors, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 20, 2019 In honor of National Lung Cancer Awareness month, Hope4Cancer Treatment Centers reported Eight Days, a groundbreaking reality TV series that tells the stories of five cancer patients and their journey using alternative cancer treatments that are working (Press release, Hope4cancer, NOV 20, 2019, View Source [SID1234551554]). The first reality TV series of its kind, Eight Days, is set to premiere on the FYI Network on January 4, 2020 and will give viewers an inside look at what healing from cancer is really like, as well as highlight new integrative cancer treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Antonio Jimenez, Hope4Cancer Founder and Chief Medical Officer, prepares to launch the first of its kind docuseries on cancer called Eight Days. The 10-episode program will air on the FYI Network and follows 5 patients and their alternative treatments at the Hope4Cancer Center.
Dr. Antonio Jimenez, Hope4Cancer Founder and Chief Medical Officer, prepares to launch the first of its kind docuseries on cancer called Eight Days. The 10-episode program will air on the FYI Network and follows 5 patients and their alternative treatments at the Hope4Cancer Center.
"Eight Days examines the lives of five diverse individuals living with different stages of cancer and the experts who guide them on their healing journey. From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms. We also see the latest breakthroughs in non-toxic cancer treatments that are having real impact on the disease," explained Hope4Cancer Founder and Chief Medical Officer, Dr. Antonio Jimenez.

The five patients highlighted in the series include Kate Malvenan, diagnosed with Stage 4 Lung Cancer. The 39-year old solo mother from Australia’s Gold Coast is determined to beat cancer for her 3-year-old daughter, Annabelle. At the time of her original diagnosis, Kate was given only six months to live, with cancer spreading throughout her spine, hips, ribs, shoulder, and liver. Refusing to give up, she arrives on Eight Days ready to embrace change with the spirit of a warrior and the strength of a mother.

"If I wasn’t a mom, I think I would have taken the diagnosis and just handled it gracefully. But being a parent, I’ve taken the gloves off, and I’m ready to fight this," says Kate Malvenan, cancer patient, Eight Days.

Additional patients include:

43-year old Carrie Crary, an active, health-conscious nurse who battles Breast Cancer for the second time.
66-year old Jose Fernandez, a pastor diagnosed with Prostate Cancer.
41-year old Nicole Randle who works to overcome Stage 3 Ovarian Cancer.
57-year old Janine Jannicelli who is diagnosed with Breast Cancer.
"We partnered with film producer, Charles Mattocks, to help us share our patients’ stories, because we know of his work as a health advocate and appreciate his passion for investigative storytelling," added Jimenez.

Charles Mattocks is an award-winning film producer who garnered media attention for his first docuseries, Reversed, where he focused on the health effects of diabetes. With over 1.7 million cancer diagnoses documented per year in the U.S. alone, Mattock takes on a health topic where the show’s content and information have the power and potential to affect millions of lives.

"It’s a show unlike anything that’s been seen before, with cancer survivors who share it all and experts who lovingly guide them to health and healing," stated Jimenez.

For more information, visit the Hope4Cancer Eight Days site.

Media Preview Trailer (is free and clear for use for broadcast, online, digital and social media postings, please courtesy "Eight Days/Hope4Cancer")

On November 20, 2019 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian J. Brille, Vice Chairman of the Company, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 12:50 p.m. Eastern Time at Lotte New York Palace Hotel, Kennedy 1 Room, in New York City (Press release, Caris Life Sciences, NOV 20, 2019, View Source [SID1234551552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Brille will present a corporate overview and discuss recent expansion and development progress that positions the Company to further extend its leadership in precision medicine. He will also take questions from the audience following the presentation.

Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Piper Jaffray representative.

On November 20, 2019 Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough therapies for patients, reported Kymera Co-founder, President and Chief Scientific Officer Nello Mainolfi, PhD, has been promoted to President and Chief Executive Officer effective immediately (Press release, Kymera Therapeutics, NOV 20, 2019, View Source [SID1234551551]). Mainolfi will lead Kymera as the company enters its next stage of growth, advancing a series of novel degrader drugs into clinical development as well as expanding the impact of its innovative Pegasus platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"On behalf of entire Board of Directors, I’m excited to recognize Nello Mainolfi as the next CEO of Kymera Therapeutics, especially at a time of exceptional growth, promising data delivery, and premier partnerships," said Bruce Booth, DPhil, Chairman of the Kymera Board of Directors and partner at Atlas Venture. "Since the inception of Kymera, Nello has demonstrated exemplary leadership and capabilities, and provided strategic direction to advance the development of our powerful new drug discovery engine from target identification into development. With a pipeline of drug candidates advancing into the clinic, we have full confidence that Nello is the best person to successfully position the company and realize the potential of this modality."

Mainolfi started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify novel potential medicines that have entered clinical development across a series of disease areas. Before co-founding Kymera with Booth in 2016, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics.

"I would like to thank the Board of Directors and the entire Kymera team for this unique opportunity," said Mainolfi. "I’ve had the privilege of contributing to the scientific and corporate evolution of Kymera and I look forward to continuing to foster its research & development progress and ambition. I’m excited to help Kymera deliver on our mission of inventing a new class of protein degrader medicines for patients."

On November 20, 2019 ViewRay, Inc. (NASDAQ: VRAY) reported that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019 (Press release, ViewRay, NOV 20, 2019, View Source [SID1234551549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.